[1]张勇,刘小燕,成小凤,等.室间隔酒精消融术后左心室流出道压差下降幅度及影响因素分析[J].第三军医大学学报,2020,42(05):499-503.
 ZHANG Yong,LIU Xiaoyan,CHENG Xiaofeng,et al.Decreasing amplitude of left ventricular outflow tract gradient and its influencing factors after alcohol septal ablation[J].J Third Mil Med Univ,2020,42(05):499-503.
点击复制

室间隔酒精消融术后左心室流出道压差下降幅度及影响因素分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第05期
页码:
499-503
栏目:
临床医学
出版日期:
2020-03-15

文章信息/Info

Title:
Decreasing amplitude of left ventricular outflow tract gradient and its influencing factors after alcohol septal ablation
作者:
张勇刘小燕成小凤李平何永铭陈佳夏红梅徐亚丽王江
陆军军医大学(第三军医大学)第二附属医院心血管内科,全军心血管病研究所
Author(s):
ZHANG Yong LIU Xiaoyan CHENG Xiaofeng LI Ping HE Yongming CHEN Jia XIA Hongmei XU Yali WANG Jiang

Department of Cardiology, Institute of Cardiology, Second Affiliated Hospital, Army Medical University(Third Military Medical University), Chongqing, 400037, China

关键词:
肥厚型心肌病肥厚型梗阻性心肌病室间隔酒精消融术左心室流出道压差
Keywords:
hypertrophic cardiomyopathy hypertrophic obstructive cardiomyopathy alcohol septal ablation left ventricular outflow tract gradient
分类号:
R540.46; R542.2; R914.4
文献标志码:
A
摘要:

目的观察室间隔酒精消融术(alcohol septal ablation,ASA)治疗肥厚型梗阻性心肌病(hypertrophic obstructive cardiomyopathy,HOCM)后左心室流出道压差(left ventricular outflow tract gradient,LVOTG)的下降幅度,并分析其影响因素。方法收集本院2011年8月至2019年8月行ASA治疗的HOCM患者58例,比较手术前后超声心动图的变化(中位随访34 d),评估术后LVOTG的下降幅度。根据LVOTG是否降低50%分为LVOTG下降显著组(LVOTG下降≥50%)及不显著组(LVOTG下降<50%),对比两组患者的临床资料,分析LVOTG下降显著的独立影响因素,并对影响因素作ROC曲线分析。结果58例患者ASA术后LVOTG为(46.13±39.31)mmHg,较术前(90.77±33.38)mmHg显著下降(P<0.05),术后室间隔厚度、左房内径、二尖瓣反流面积、二尖瓣收缩期前向运动征均显著减少(P<0.05)。多因素logistic回归分析显示,酒精剂量(OR 3.222,95%CI:1.345~7.717,P=0.009)是短期LVOTG下降显著的独立影响因素,ROC曲线下面积(AUC)为0.707(95%CI:0.573~0.841,P=0.009)。结论ASA可有效降低HOCM患者的LVOTG,接受高剂量酒精消融的患者LVOTG下降的幅度更显著。

Abstract:

Objective To analyze the decreasing amplitude of left ventricular outflow tract gradient(LVOTG) and its influencing factors after alcohol septal ablation(ASA) in treatment of hypertrophic obstructive cardiomyopathy(HOCM). Methods A total of 58 HOCM patients treated by ASA in our hospital from August 2011 to August 2019 were recruited in this study. The changes of echocardiography before and after ASA(a median follow-up period of 34 d) were compared to evaluate the decreasing amplitude of LVOTG after surgery. According to whether the LVOTG was decreased by 50%, the patients were divided into the significant LVOTG decline group(LVOTG decline ≥50%) and the non-significant decline group(LVOTG decline <50%). The clinical data were compared between the 2 groups. The independent influential factors of significant LVOTG decline were analyzed, and receiver operation characteristic(ROC) curve analysis was also performed for the influencing factors. ResultsThe LVOTG of the 58 patients was decreased from 90.77±33.38 mmHg preoperatively to 46.13±39.31 mmHg(P<0.05). The interventricular septum thickness, left atrial diameter, mitral regurgitation area and systolic anterior motion were all significantly reduced after surgery (P<0.05). Multivariate logistic regression analysis indicated that alcohol dose(OR=3.222, 95%CI: 1.345~7.717, P=0.009) was an independent influencing factor of significant LVOTG decline in short term, with the area under curve(AUC) of 0.707(95%CI: 0.573~0.841, P=0.009). ConclusionASA can effectively reduce LVOTG in HOCM patients. And the higher the alcohol dose is, the more significant the decreasing amplitude is.

参考文献/References:

[1]AUTHORS/TASK FORCE MEMBERS, ELLIOTT P M, ANASTASAKIS A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology(ESC)[J]. Eur Heart J, 2014, 35(39): 2733-2779. DOI:10.1093/eurheartj/ehu284. 
[2]中国医师协会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会,张健,等. 中国肥厚型心肌病管理指南2017[J]. 中华心力衰竭和心肌病杂志, 2017, 1(2): 65-86. DOI: 10.3760/cma.j.issn.2096-3076.2017.12.001.
Heart Failure Professional Commission of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy, ZHANG J, et al. Chinese guildelines on the management of hypertrophic cardiomyopathy 2017[J]. Chin J Heart Fail Cardiomyopathy, 2017,1(2): 65-86. DOI: 10.3760/cma.j.issn.2096-3076.2017.12.001.
[3]SEMSARIAN C, INGLES J, MARON M S, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2015, 65(12): 1249-1254. DOI:10.1016/j.jacc.2015.01.019.
[4]SIGWART U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet, 1995, 346(8969): 211-214. DOI:10.1016/s0140-6736(95)91267-3.
[5]VESELKA J, LAWRENZ T, STELLBRINK C, et al. Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicenter and multinational study[J]. Catheter Cardiovasc Interv, 2014, 84(1): 101-107. DOI:10.1002/ccd.25236.
[6]AGUIAR ROSA S, FIARRESGA A, GALRINHO A, et al. Short- and long-term outcome after alcohol septal ablation in obstructive hypertrophic cardiomyopathy: Experience of a reference center[J]. Rev Port Cardiol, 2019, 38(7): 473-480. DOI:10.1016/j.repc.2019.08.003. 
[7]肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识组. 肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识[J]. 中国心血管病研究, 2012, 10(1): 1-7. DOI:10.3969/j.issn.1672-5301.2012.01.001.
China Expert Consensus Group of Hypertrophic Obstructive Cardiomyopathy Septal Myocardial Ablation. China expert consensus of hypertrophic obstructive cardiomyopathy septal myocardial ablation [J]. Chin J Cardiovasc Rev, 2012, 10(1): 1-7. DOI:10.3969/j.issn.1672-5301.2012.01.001.
[8]RIGOPOULOS A G, SAKELLAROPOULOS S, ALI M, et al. Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results[J]. Heart Fail Rev, 2018, 23(6): 907-917. DOI: 10.1007/s10741-018-9706-z.
[9]AN S Y, YANG Y J, HANG F, et al. Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China[J]. Sci Rep, 2017, 7(1): 9506. DOI: 10.1038/s41598-017-10144-0.
[10]VESELKA J, JENSEN M K, LIEBREGTS M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry[J]. Eur Heart J, 2016, 37(19): 1517-1523. DOI:10.1093/eurheartj/ehv693.
[11]SAWAYA F J, LOUVARD Y, SPAZIANO M, et al. Short and long-term outcomes of alcohol septal ablation with the trans-radial versus the trans-femoral approach: a single center-experience[J]. Int J Cardiol, 2016, 220: 7-13. DOI:10.1016/j.ijcard.2016.06.127.
[12]LIEBREGTS M, STEGGERDA R C, VRIESENDORP P A, et al. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly[J]. JACC Cardiovasc Interv, 2016, 9(5): 463-469. DOI:10.1016/j.jcin.2015.11.036.
[13]BATZNER A, PFEIFFER B, NEUGEBAUER A, et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol, 2018, 72(24): 3087-3094. DOI:10.1016/j.jacc.2018.09.064. 
[14]STEGGERDA R C, DAMMAN K, BALT J C, et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience[J]. JACC Cardiovasc Interv, 2014, 7(11): 1227-1234. DOI: 10.1016/j.jcin.2014.05.023.
[15]VESELKA J, TOMAOV P, ZEMNEK D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years[J]. Can J Cardiol, 2011, 27(6): 763-767. DOI:10.1016/j.cjca.2011.09.001.
[16]NAGUEH S F, GROVES B M, SCHWARTZ L, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry[J]. J Am Coll Cardiol, 2011, 58(22): 2322-2328. DOI:10.1016/j.jacc.2011.06.073.
[17]FORTUNATO DE CANO S, NICOLAS CANO M, DE RIBAMAR COSTA J Jr, et al. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy[J]. Catheter Cardiovasc Interv, 2016, 88(6): 953-960. DOI:10.1002/ccd.26430.
[18]VESELKA J, TOMASOV P, JANUSKA J, et al. Obstruction after alcohol septal ablation is associated with cardiovascular mortality events[J]. Heart, 2016, 102(22): 1793-1796. DOI:10.1136/heartjnl-2016-309699.
[19]KASHTANOV M G, RZHANNIKOVA A D, CHERNYSHEV S D, et al. Outcomes of hypertrophic obstructive cardiomyopathy patients undergoing alcohol septal ablation with a standard 3 mL dose of ethanol: Focus on long-term safety[J]. Catheter Cardiovasc Interv, 2019. [Epub ahead of print]. DOI: 10.1002/ccd.28499.

相似文献/References:

[1]黄海韵,郭燕丽,孟璟,等.斑点追踪成像在肥厚型梗阻性心肌病患者室间隔酒精消融术后随访中的应用价值[J].第三军医大学学报,2015,37(18):1859.
 Huang Haiyun Guo Yanli,Meng Jing,Hu Houyuan,et al.Value of speckle tracking imaging in postoperative follow-up of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: report of 19 cases[J].J Third Mil Med Univ,2015,37(05):1859.
[2]邓丹,孟璟,曲小龙,等.室间隔化学消融术治疗肥厚型梗阻性心肌病的临床疗效分析[J].第三军医大学学报,2017,39(16):1673.
 DENG Dan,MENG Jing,QU Xiaolong,et al.Clinical efficacy and safety of alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J].J Third Mil Med Univ,2017,39(05):1673.

更新日期/Last Update: 2020-03-06